- Zydus Lifesciences Ltd and Guardant Health announce their support for the newly launched LiS
- The aim through LiS Academy is to support clinicians and bring in a greater understanding and awareness on precision oncology and enable better patient care: Samir Desai
- By empowering oncologists with the awareness of liquid biopsies, we can accelerate access to personalised treatment and improve outcomes for more patients across the cancer continuum in India: Simranjit Singh
NE HEALTH BUREAU
NEW DELHI, FEB 19
Zydus Lifesciences Ltd., a global innovation driven healthcare company and Guardant Health, a leading precision oncology company, announced their support for the newly launched Liquid is Solid® (LiS) Academy’s educational effort.
Established and driven by leading oncologists, the LiS academy is an independent academic forum and a first-of-its-kind initiative in India, which is focused on increasing the awareness of precision medicine using liquid biopsies (minimally invasive blood-based tests) in transforming cancer care.
“Precision medicine and liquid biopsy represent the future of oncology. However, without widespread awareness, its potential remains untapped,” said Dr. T. Raja, Sr consultant & Director of Medical Oncology at Apollo Cancer Centre, Chennai. “LiS Academy aims to bridge this gap by equipping doctors with the knowledge and resources needed to implement liquid biopsies effectively in cancer care and empower patients with increased awareness,” Dr. T. Raja added.
With one in nine people likely to develop cancer in his or her lifetime in India, cutting-edge diagnostic solutions can play a critical role in reducing the burden of cancer by helping clinicians to detect cancer early, monitor recurrence and identify targeted treatment strategies with a simple blood draw.
“Our focus in oncology care is to help patients through a holistic approach right from accessing affordable therapies, to companion diagnostics, nutrition and counselling. The aim through LiS Academy is to support clinicians and bring in a greater understanding and awareness on precision oncology and enable better patient care.” said Samir Desai, President, BU Biologics, Zydus Lifesciences Limited. “By fostering collaboration between clinicians, researchers, and industry leaders, we can accelerate the adoption of these life-saving technologies,” Samir Desai added.
“The launch of LiS Academy marks a pivotal step in bringing transformative cancer care to India. By empowering oncologists with the awareness of liquid biopsies, we can accelerate access to personalised treatment and improve outcomes for more patients across the cancer continuum in India,” said Simranjit Singh, CEO of Guardant Health AMEA. “We are committed to fostering a future where healthcare is data-driven and patient-centric,” Simranjit Singh added.
“Structured programs through the LiS Academy provide clinicians with a solid foundation in understanding and utilising liquid biopsy technologies,” said Dr. Nitesh Rohatgi, Senior Director Medical Oncology at Fortis Memorial Research Institute, Gurugram.
“Peer mentoring also ensures that the learning goes beyond theoretical knowledge, empowering doctors to confidently integrate these innovations into their practice and improve patient outcomes,” Dr. Nitesh Rohatgi added.
With cancer incidences on the rise, the continuous effort to bridge knowledge gaps which limit healthcare innovations is paramount.
